SAN DIEGO & SAN CARLOS, Calif.--(BUSINESS WIRE)--July 20, 2006--Illumina, Inc. (NASDAQ: ILMN - News) and ReaMetrix, Inc. announced today the formation of a diagnostic collaboration under which the companies plan to co-develop molecular diagnostic panels for a range of disease areas. Under the terms of the agreement, ReaMetrix will gain non-exclusive rights to market the resulting panels to the country of India and its more than one billion inhabitants. Illumina will retain rights to market the tests outside of India.
